In addition, recently, the guideline-based medical therapy (GDMT) for HF included sodium–glucose cotransporter (SGLT) 2 inhibitors [28] because SGLT2 inhibitors have been to have a strong clinical impact on HF [29,30]. The gene discussed is SLC5A2; the disease is hydrops fetalis.